Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2015
Matèries:
Cancer Therapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://ncbi.nlm.nih.gov/pubmed/25080865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars